(PDEX) Pro-Dex - Overview
Stock: Surgical, Motors, Instruments, Medical, Motors, Services
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 56.6% |
| Relative Tail Risk | -12.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.54 |
| Alpha | 12.31 |
| Character TTM | |
|---|---|
| Beta | 0.441 |
| Beta Downside | 0.116 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.36% |
| CAGR/Max DD | 0.51 |
Description: PDEX Pro-Dex January 17, 2026
Pro-Dex, Inc. (NASDAQ:PDEX) designs, develops, manufactures, and sells powered surgical instruments-primarily autoclavable, battery-powered, and electric drivers and shavers-for original equipment manufacturers (OEMs) in the orthopedic, thoracic, and craniomaxillofacial markets. The firm also offers engineering, quality, and regulatory consulting services and produces rotary air motors for non-medical industries.
Founded in 1978 and headquartered in Irvine, California, Pro-Dex operates as a pure-play health-care equipment company (GICS sub-industry) serving hospitals, medical engineering labs, research facilities, and high-tech manufacturers worldwide.
Based on the most recent Form 10-K (FY 2023), the company reported revenue of roughly **$84 million**, with a **gross margin of ~38 %** and a **year-over-year revenue growth of 5 %**. (Assumption: FY 2024 guidance will track the same growth trajectory; uncertainty remains around OEM demand cycles and supply-chain constraints.)
Key sector drivers include an aging U.S. population that is projected to increase total joint replacement procedures by ~4 % annually through 2030, and a shift toward minimally invasive surgery that boosts demand for battery-powered, ergonomically designed instruments. Additionally, the global orthopedic device market is valued at **≈$55 billion** (2023) with a CAGR of ~5 % (base-rate from industry reports), providing a sizable addressable market for Pro-Dex’s niche product line.
For a deeper, data-driven valuation of PDEX, consider exploring ValueRay’s analytical tools to complement this high-level overview.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 11.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 7.23 > 1.0 |
| NWC/Revenue: 51.30% < 20% (prev 44.52%; Δ 6.77% < -1%) |
| CFO/TA 0.10 > 3% & CFO 6.46m > Net Income 11.3m |
| Net Debt (2.94m) to EBITDA (17.4m): 0.17 < 3 |
| Current Ratio: 4.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.30m) vs 12m ago -1.00% < -2% |
| Gross Margin: 28.29% > 18% (prev 0.30%; Δ 2799 % > 0.5%) |
| Asset Turnover: 117.6% > 50% (prev 101.0%; Δ 16.55% > 0%) |
| Interest Coverage Ratio: 19.80 > 6 (EBITDA TTM 17.4m / Interest Expense TTM 814.0k) |
Altman Z'' 9.96
| A: 0.59 (Total Current Assets 49.2m - Total Current Liabilities 12.2m) / Total Assets 62.3m |
| B: 0.67 (Retained Earnings 41.6m / Total Assets 62.3m) |
| C: 0.26 (EBIT TTM 16.1m / Avg Total Assets 61.3m) |
| D: 2.02 (Book Value of Equity 41.6m / Total Liabilities 20.6m) |
| Altman-Z'' Score: 9.96 = AAA |
Beneish M -1.33
| DSRI: 0.83 (Receivables 18.1m/18.5m, Revenue 72.1m/61.0m) |
| GMI: 1.06 (GM 28.29% / 30.02%) |
| AQI: 3.64 (AQ_t 0.20 / AQ_t-1 0.05) |
| SGI: 1.18 (Revenue 72.1m / 61.0m) |
| TATA: 0.08 (NI 11.3m - CFO 6.46m) / TA 62.3m) |
| Beneish M-Score: -1.33 (Cap -4..+1) = D |
What is the price of PDEX shares?
Over the past week, the price has changed by +0.56%, over one month by -3.69%, over three months by +21.05% and over the past year by +14.88%.
Is PDEX a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PDEX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 56 | 42% |
| Analysts Target Price | 56 | 42% |
| ValueRay Target Price | 43.3 | 9.8% |
PDEX Fundamental Data Overview February 01, 2026
P/E Forward = 18.797
P/S = 1.8221
P/B = 3.0211
Revenue TTM = 72.1m USD
EBIT TTM = 16.1m USD
EBITDA TTM = 17.4m USD
Long Term Debt = 8.01m USD (from longTermDebt, last quarter)
Short Term Debt = 2.47m USD (from shortTermDebt, last quarter)
Debt = 10.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.94m USD (from netDebt column, last quarter)
Enterprise Value = 130.9m USD (128.0m + Debt 10.9m - CCE 7.95m)
Interest Coverage Ratio = 19.80 (Ebit TTM 16.1m / Interest Expense TTM 814.0k)
EV/FCF = 21.15x (Enterprise Value 130.9m / FCF TTM 6.19m)
FCF Yield = 4.73% (FCF TTM 6.19m / Enterprise Value 130.9m)
FCF Margin = 8.59% (FCF TTM 6.19m / Revenue TTM 72.1m)
Net Margin = 15.73% (Net Income TTM 11.3m / Revenue TTM 72.1m)
Gross Margin = 28.29% ((Revenue TTM 72.1m - Cost of Revenue TTM 51.7m) / Revenue TTM)
Gross Margin QoQ = 30.77% (prev 28.96%)
Tobins Q-Ratio = 2.10 (Enterprise Value 130.9m / Total Assets 62.3m)
Interest Expense / Debt = 1.29% (Interest Expense 141.0k / Debt 10.9m)
Taxrate = 25.31% (741.0k / 2.93m)
NOPAT = 12.0m (EBIT 16.1m * (1 - 25.31%))
Current Ratio = 4.03 (Total Current Assets 49.2m / Total Current Liabilities 12.2m)
Debt / Equity = 0.26 (Debt 10.9m / totalStockholderEquity, last quarter 41.6m)
Debt / EBITDA = 0.17 (Net Debt 2.94m / EBITDA 17.4m)
Debt / FCF = 0.47 (Net Debt 2.94m / FCF TTM 6.19m)
Total Stockholder Equity = 38.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.49% (Net Income 11.3m / Total Assets 62.3m)
RoE = 29.25% (Net Income TTM 11.3m / Total Stockholder Equity 38.8m)
RoCE = 34.46% (EBIT 16.1m / Capital Employed (Equity 38.8m + L.T.Debt 8.01m))
RoIC = 22.66% (NOPAT 12.0m / Invested Capital 53.1m)
WACC = 7.02% (E(128.0m)/V(138.9m) * Re(7.54%) + D(10.9m)/V(138.9m) * Rd(1.29%) * (1-Tc(0.25)))
Discount Rate = 7.54% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -13.40%
[DCF Debug] Terminal Value 74.90% ; FCFF base≈4.37m ; Y1≈2.87m ; Y5≈1.31m
Fair Price DCF = 8.76 (EV 31.0m - Net Debt 2.94m = Equity 28.1m / Shares 3.21m; r=7.02% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 41.07 | EPS CAGR: -11.52% | SUE: -1.57 | # QB: 0
Revenue Correlation: 92.60 | Revenue CAGR: 20.53% | SUE: 0.78 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.62 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-06-30): EPS=2.38 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=-10.9% | Growth Revenue=+5.1%